Evidence map›Paper›PMID 41001365›Full record

ArticleFrontiers in medicine2025

A real-world study of polyenyl phosphatidylcholine in the management of patients with metabolic dysfunction-associated fatty liver disease in China clinical practice.

Yi Pan, Feng Xue, Shanshan Wang, Bihui Zhong, Yutao Zhan, Qi Wang, Youqing Xu, Huiying Rao, Yuqiang Mi, Yuemin Nan and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yi PanBeijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
Feng XueBeijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
Shanshan WangBeijing North Medical and Health Economic Research Center, Beijing, China.
Bihui ZhongDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Yutao ZhanDepartment of Gastroenterology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Qi WangCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Youqing XuDepartment of Gastroenterology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Huiying RaoPeking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
Yuqiang MiClinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China.
Yuemin NanDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, China.
Xiaoyuan XuDepartment of Gastroenterology, Peking University First Hospital, Beijing, China.
Branko PopovicNattermann & Cie. GmbH, Frankfurt am Main, Germany.
Xiaoqing LiOpella, Beijing, China.
Bruno ScarpelliniOpella, São Paulo, Brazil.
Sabine TongOpella, Neuilly-sur-Seine, France.
Lai WeiBeijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Objectives: Metabolic dysfunction-associated fatty liver disease (MAFLD) is highly prevalent in China. Clinical evidence supporting the role of polyenyl phosphatidylcholine (PPC) in delaying liver fibrosis in patients with MAFLD is limited. Hence this study evaluated the effectiveness of PPC and its association with delaying progression of liver fibrosis in patients with MAFLD in China. Methods: This multicenter, retrospective observational study included patients with type 2 diabetes mellitus or ≥2 metabolic dysregulations. Patients from the MAFLD cohort were divided into two groups to receive either PPC or control (no hepatoprotective treatment). The primary endpoint was the change in baseline fibrosis (FIB)-4 index at 12 and 24 weeks. The secondary endpoint involved comparison of changes in liver enzymes and blood lipid levels. Results: Among 22,705 patients with MAFLD who were treated with hepatoprotective drugs, 7,093 received PPC. Significant reduction in baseline fibrosis was observed at 24 weeks (PPC: -0.12 ± 0.62 vs. control: 0.11 ± 0.50, Conclusion: PPC treatment can lower the risk of liver fibrosis and improve liver function and lipid profiles. Further validation is warranted in other ethnic groups in larger cohorts.

Indexed as

Chinaessential phospholipidshepatic fibrosisMAFLDmetabolic dysfunction-associated fatty liver diseasepolyenyl phosphatidylcholinereal-world study

Identifiers

PMID41001365
PMCPMC12457410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.